CIP2Aは,ヒトの悪性腫瘍におけるPP2Aを阻害する.
Melissa R Junttila1, Pietri Puustinen, Minna Niemelä
1Centre for Biotechnology, University of Turku and Abo Akademi University, 20520 Turku, Finland.
Cell
|July 17, 2007
まとめ
PP2A (PP2A) の癌性阻害剤 (CIP2A) は,タンパク質フォスファタゼ2A (PP2A) の活性を阻害する,新たに特定されたオンコタンパク質です. CIP2Aは,腫瘍性転写因子c-Mycを安定させ,ヒトの癌発症を促進する.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- タンパク質フォスファタゼ2A (PP2A) 抑制は,ヒト細胞の変容に不可欠です.
- 人間のがんにおけるPP2A阻害の分子メカニズムは,依然としてほとんど不明である.
研究 の 目的:
- 腫瘍性活性を持つPP2Aの細胞性阻害剤を特定し,特徴づけること.
- ヒトの悪性腫瘍におけるこの阻害剤の役割を解明する.
主な方法:
- CIP2A.を特定するためのタンパク質相互作用の研究.
- PP2A阻害を測定するための酵素活性アッセイ.
- 変容と腫瘍形成のための細胞解析.
- 人間のがんにおけるCIP2A発現の分析.
主要な成果:
- PP2Aの癌性阻害剤 (CIP2A) という新しいタンパク質が,PP2A阻害剤として特定されました.
- CIP2Aはc-Mycと直接相互作用し,セリン62 (S62) でPP2Aの活性を抑制する.
- CIP2Aはc-Mycの分解を防止し,アンカレージ独立成長を促進し,腫瘍形成を誘発する.
- CIP2Aは,頭頸部状細胞癌 (HNSCC) と大腸がんにおいて過剰発現している.
結論:
- CIP2Aは,PP2Aを阻害し,c-Myc.を安定させるヒトオンコタンパク質です.
- CIP2Aは,ヒトの悪性腫瘍の発生に重要な役割を果たしています.
関連する概念動画
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...